ADVFN ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Credit Suisse X-Links Long/Short Equity Etn

Credit Suisse X-Links Long/Short Equity Etn (CSLS)

27.9899
0.00
(0.00%)
Cerrado 10 Julio 3:00PM
0.00
0.00
(0.00%)
Fuera de horario: -

Credit Suisse X-Links Long/Short Equity Etn (CSLS) Cotización

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
27.9899
( - )
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Precio Anterior
27.9899
Precio de Apertura
-
Hora
Última hora de negociación
Volumen promedio (3 m)
-
Volumen financiero
-
Precio Promedio Ponderado
-

CSLS Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CSLS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Credit Suisse X-Links Long/Short Equity Etn?
El precio actual de las acciones de Credit Suisse X-Links Long/Short Equity Etn es US$ 27.9899
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Credit Suisse X-Links Long/Short Equity Etn?
Credit Suisse X-Links Long/Short Equity Etn ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año

CSLS Operaciones

Más

Operaciones con retraso

Para obtener operaciones en tiempo real, actualice su cuenta

Actualizar a tiempo real
rosemountbomber rosemountbomber 24 minutos hace
It is the consensus view because company management and the FDA have not given us reason to believe otherwise.  As far as the AI take in your following post how ridiculous that the 2nd CRL to cite the same deficiencies as the first. They never did a second inspection to discover those deficiencies.
UNCY
Genz2 Genz2 26 minutos hace
https://www.macrumors.com/2026/07/09/apple-prismml-larger-on-device-ai-models/

Has Tesla/SpaceXAI thought about working with a company like PrismML so that they could efficiently run Grok/MacroHard and use less memory in Dell, HP or Lenovo computers? The PrismML could reduce the memor
TSLA
Slojab Slojab 26 minutos hace
Pretty ridiculous, huh? You should be able to have a negative market cap. 🤣
GRLF
smoki smoki 29 minutos hace
F’ing A ….blasting off get your free ride NOW!!! $$$$$$$$$ …Blozf goos Blo ^^^^^^^^^^^^:))))))
BLOZF
BahamaPete BahamaPete 36 minutos hace
Thanks OCKHAM's RAZOR, I added your links to my DD post. Go $TKOI
TKOI
Helter Skelter Helter Skelter 45 minutos hace
😆 "accurately captures one of the most critical underappreciated alliances..."

https://investorshub.advfn.com/uimage/uploads/2026/7/10/opnhmBB_Can_u_say_MONOPOLY_071026.png

🤑 $BB Where Nvidia Goes We Go $NVDA 🤑
BB
Twiggs333 Twiggs333 52 minutos hace
CMPS Compass Pathways: A Structural Mispricing in Plain Sight?

Extremely good explanation of the value of this company by a Stanford Professor.

https://x.com/kevin__mak/status/2075541715272790373
CMPS
Popeye Popeye 52 minutos hace
Yeah, agreed. That was a shot of the dark guess of the discount for the Reg A and .08 would certainly move the numbers in the favor of the shareholder. 
Unknowns are 1. What will the discount be and 2. How much will Korenko raise? (Doesn’t have to raise the entire $9 million now - maybe raise
RDGL
Twiggs333 Twiggs333 54 minutos hace
Compass Pathways: A Structural Mispricing in Plain Sight?

https://x.com/kevin__mak/status/2075541715272790373
CMPS
CA Market News CA Market News 57 minutos hace
Lion One Announces Closing of Second Tranche of Non-Brokered Private Placement of Convertible Debenture Units and Units for Aggregate Gross Proceeds of $17.5 MillionJuly 10, 2026 11:14 PM
Newsfile
LOMLF
Genz2 Genz2 1 hora hace
Sorry, misspelled Greg’s last name in the previous post!!! It should be Kazmierczak!!
Gus1212 Gus1212 1 hora hace
If this rejection theory is correct, I believe it was just a tactic to stall our approval process.
Sounds too simple, doesn't it!

Maybe paid for by you know who, big pharma.

They all know that DCVAX works; they are not dummies.
Why did they stall? Cou
NWBO
Whalatane Whalatane 1 hora hace
A Fable 5 analysis
Synthesized FDA timeline risks, TDAPA reimbursement implications, and dilution concernsSynthesized FDA timeline risks, TDAPA reimbursement implications, and dilution concernsGood context to layer in.
Here's the deeper risk breakdown on those three fronts.
UNCY
LTR LTR 1 hora hace
I think a suitable punishment for these guys would be to lock them up in ILT's vault and throw away the key.
NWBO
Real McCoy Real McCoy 1 hora hace
Well yeah this one has the most lies.

3rd attempt: you ok with lies, yes or no?
pos_stock_hoarder pos_stock_hoarder 1 hora hace
New York Dolls - Looking for a Kiss

https://youtu.be/GvmvMFXWzc8
Genz2 Genz2 1 hora hace
https://techcrunch.com/2026/07/10/us-cyber-agency-cisa-had-to-build-its-incident-playbook-during-the-incident-agency-reveals/

According to Krebs, the researcher tried to alert the contractor but didn’t hear back. Only after Krebs contacted CISA did the agency take the repository offli
boston127 boston127 1 hora hace
Hey,

Thanks for the links you sent me. My PC blocked all of the URLs due to malware protection. I'm still in GNIS and the other one. I was up but they have dive bombed quite rapidly. Now, in the RED. Both companies are interesting.
TKOI
LTR LTR 1 hora hace
I have an idea AF may turn up in discovery when the dots are lined up and connected. AF may look to be a witness in order to avoid being a defendent.
NWBO
conix conix 1 hora hace
Non-promotional information until there is a press release is a wise move.
CUBT
CatfishHunter CatfishHunter 1 hora hace
We should have news of next step well before years end. Vivos is already approved by FDA to start the EFS. Mayo Clinic needs to review and sign off on the approved conditions for the IRB and that’s just a formality. EFS could start as early as August. And 30 day patient status report about 45 days a
RDGL
Philosophical Trader Philosophical Trader 1 hora hace
How is this doing? This was a great runner with a 2 year cup and handle.
KRFG
nwtf nwtf 1 hora hace
You really dont have a clue what you are talking about. Just stop.
DBMM

Su Consulta Reciente